Profile data is unavailable for this security.
About the company
Frontage Holdings Corporation is a holding company. The principal activities of the Company and its subsidiaries are to provide laboratory and related services to pharmaceutical and agrochemical companies. The Company is a contract research organization (CRO) providing integrated, science-driven, product development services throughout the drug discovery and development process to enable life science companies to achieve their drug development goals. Its segments include North America and the People’s Republic of China (PRC). The North America segment includes laboratory testing, chemistry, manufacturing and control (CMC), preclinical research, early stage clinical/bioequivalence and chemistry services in the USA and Canada. PRC segments include laboratory testing, CMC, preclinical research, early stage clinical/ bioequivalence and chemistry services in the PRC. Its preclinical research services consist of drug metabolism and pharmacokinetic (DMPK) and safety and toxicology.
- Revenue in HKD (TTM)2.03bn
- Net income in HKD84.41m
- Incorporated2018
- Employees1.76k
- LocationFrontage Holdings Corp700 Pennsylvania DrExton 19341-1129United StatesUSA
- Phone+1 (610) 232-0100
- Fax+1 (610) 232-0101
- Websitehttps://www.frontagelab.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sunho Biologics Inc | -100.00bn | -100.00bn | 1.01bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -155.25 | -- | -- | -- |
| Jacobio Pharmaceuticals Group Co Ltd | 68.18m | -385.46m | 1.32bn | 301.00 | -- | 1.15 | -- | 19.34 | -0.4986 | -0.4986 | 0.0882 | 1.46 | 0.0419 | -- | 5.21 | 226,508.40 | -23.66 | -45.76 | -26.86 | -49.30 | 5.04 | -- | -565.36 | -372.22 | -- | -- | 0.1636 | -- | -33.66 | -- | 3.43 | -- | 19.18 | -- |
| Hua Medicine | 82.23m | -226.73m | 1.38bn | 177.00 | -- | 11.83 | -- | 16.82 | -0.232 | -0.232 | 0.0842 | 0.1107 | 0.0538 | 1.69 | 13.03 | 464,571.50 | -14.84 | -25.61 | -17.56 | -28.81 | 48.78 | -- | -275.73 | -1,654.70 | 6.06 | -- | 0.6238 | -- | 335.31 | -- | -3.80 | -- | 14.07 | -- |
| Wuhan YZY Biopharma Co Ltd | 0.00 | -205.76m | 1.45bn | 123.00 | -- | 10.57 | -- | -- | -1.11 | -1.11 | 0.00 | 0.7068 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | 1.41 | -100.12 | 0.4138 | -- | -- | -- | -1.50 | -- | -- | -- |
| Mabpharm Ltd | 93.55m | -224.71m | 1.48bn | 347.00 | -- | 6.75 | -- | 15.87 | -0.0545 | -0.0545 | 0.0227 | 0.0534 | 0.0893 | 0.1176 | 6.02 | 269,608.20 | -21.44 | -21.42 | -28.92 | -27.49 | 86.32 | -- | -240.19 | -486.40 | 0.7596 | -19.03 | 0.5591 | -- | 55.87 | -- | 0.694 | -- | -26.85 | -- |
| TOT Biopharm International Co Ltd | 837.89m | -40.53m | 1.51bn | 551.00 | -- | 2.06 | 289.65 | 1.81 | -0.0559 | -0.0559 | 1.16 | 0.9538 | 0.5808 | 1.87 | 8.03 | 1,520,665.00 | -2.81 | -20.01 | -3.72 | -25.21 | 73.53 | 74.74 | -4.84 | -68.53 | 1.48 | -4.60 | 0.3348 | -- | 76.54 | 81.88 | 24.36 | -- | 21.04 | -- |
| CStone Pharmaceuticals | 497.86m | -394.17m | 1.55bn | 230.00 | -- | 3.17 | -- | 3.12 | -0.3125 | -0.3125 | 0.3942 | 0.3818 | 0.2811 | 2.44 | 3.72 | 2,164,625.00 | -22.25 | -54.76 | -48.85 | -81.68 | 65.60 | -- | -79.17 | -301.62 | 1.44 | -- | 0.4431 | -- | -3.64 | -- | 59.32 | -- | 52.42 | -- |
| Immunotech Biopharm Ltd | 0.00 | -359.38m | 1.57bn | 211.00 | -- | 8.45 | -- | -- | -0.6984 | -0.6984 | 0.00 | 0.3621 | 0.00 | -- | -- | 0.00 | -38.88 | -37.42 | -50.88 | -45.48 | -- | -- | -- | -- | 1.03 | -2.51 | 0.4327 | -- | -- | -- | -5.25 | -- | -8.46 | -- |
| Frontage Holdings Corp | 2.03bn | 84.38m | 1.59bn | 1.76k | 19.10 | 0.5933 | 4.39 | 0.7827 | 0.0408 | 0.0408 | 0.9802 | 1.31 | 0.463 | 60.63 | 5.32 | 1,153,334.00 | 1.91 | 4.46 | 2.33 | 5.28 | 30.17 | 34.00 | 4.13 | 9.92 | 1.39 | 4.09 | 0.296 | 0.00 | 3.79 | 25.61 | -58.00 | -0.7826 | 40.43 | -- |
| Laekna Inc | 0.00 | -395.87m | 1.65bn | 89.00 | -- | 1.91 | -- | -- | -3.28 | -3.28 | 0.00 | 2.21 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -5.28 | 0.0655 | -- | -- | -- | 52.81 | -- | -- | -- |
| Abbisko Cayman Ltd | 20.46m | -463.24m | 2.09bn | 258.00 | -- | 1.00 | -- | 101.99 | -0.7157 | -0.7157 | 0.0316 | 3.03 | 0.0083 | -- | 1.40 | 79,294.59 | -18.74 | -- | -19.67 | -- | 100.00 | -- | -2,264.34 | -- | -- | -- | 0.0177 | -- | -- | -- | 12.92 | -- | -- | -- |
| Alphamab Oncology | 234.82m | -226.04m | 2.13bn | 435.00 | -- | 1.19 | -- | 9.08 | -0.2351 | -0.2351 | 0.2446 | 1.86 | 0.1028 | 0.7705 | 19.34 | 539,817.30 | -9.90 | -18.72 | -11.69 | -21.94 | 74.75 | -- | -96.26 | -415.55 | 5.55 | -- | 0.1333 | -- | 31.12 | -- | 35.35 | -- | -13.12 | -- |
Data as of Jul 24 2024. Currency figures normalised to Frontage Holdings Corp's reporting currency: Hong Kong Dollar HKD
4.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Grandeur Peak Global Advisors LLCas of 30 Apr 2024 | 24.86m | 1.22% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 21.32m | 1.05% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 8.78m | 0.43% |
| First Seafront Fund Management Co., Ltd.as of 31 Dec 2023 | 8.31m | 0.41% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2022 | 7.29m | 0.36% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 6.29m | 0.31% |
| Dimensional Fund Advisors LPas of 03 Jul 2024 | 5.75m | 0.28% |
| Bellecapital AGas of 28 Dec 2023 | 4.41m | 0.22% |
| Fidelity Management & Research Co. LLCas of 30 Apr 2024 | 3.76m | 0.19% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 2023 | 3.56m | 0.18% |
More ▼
Data from 31 Dec 2023 - 17 Jul 2024Source: FactSet Research Systems Inc.
